KR102232595B1 - 치환된 피리미딘 bmi-1 저해제 - Google Patents

치환된 피리미딘 bmi-1 저해제 Download PDF

Info

Publication number
KR102232595B1
KR102232595B1 KR1020167008197A KR20167008197A KR102232595B1 KR 102232595 B1 KR102232595 B1 KR 102232595B1 KR 1020167008197 A KR1020167008197 A KR 1020167008197A KR 20167008197 A KR20167008197 A KR 20167008197A KR 102232595 B1 KR102232595 B1 KR 102232595B1
Authority
KR
South Korea
Prior art keywords
pyrimidine
benzimidazol
diamine
phenyl
methyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020167008197A
Other languages
English (en)
Korean (ko)
Other versions
KR20160048920A (ko
Inventor
우 두
라밀 바이아지토브
창선 이
영춘 문
스티븐 디. 페이젯
홍유 렌
나디야 시도렌코
리처드 제랄드 와일드
Original Assignee
피티씨 테라퓨틱스, 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 피티씨 테라퓨틱스, 인크. filed Critical 피티씨 테라퓨틱스, 인크.
Publication of KR20160048920A publication Critical patent/KR20160048920A/ko
Application granted granted Critical
Publication of KR102232595B1 publication Critical patent/KR102232595B1/ko
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020167008197A 2013-08-30 2013-11-21 치환된 피리미딘 bmi-1 저해제 Expired - Fee Related KR102232595B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361872091P 2013-08-30 2013-08-30
US61/872,091 2013-08-30
PCT/US2013/071216 WO2015030847A1 (en) 2013-08-30 2013-11-21 Substituted pyrimidine bmi-1 inhibitors

Publications (2)

Publication Number Publication Date
KR20160048920A KR20160048920A (ko) 2016-05-04
KR102232595B1 true KR102232595B1 (ko) 2021-03-26

Family

ID=52587180

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020167008197A Expired - Fee Related KR102232595B1 (ko) 2013-08-30 2013-11-21 치환된 피리미딘 bmi-1 저해제

Country Status (16)

Country Link
US (1) US10370371B2 (https=)
EP (1) EP3039015B1 (https=)
JP (2) JP6524094B2 (https=)
KR (1) KR102232595B1 (https=)
CN (1) CN105683166B (https=)
AR (1) AR093580A1 (https=)
AU (2) AU2013399092A1 (https=)
CA (1) CA2922657C (https=)
CL (1) CL2016000466A1 (https=)
EA (1) EA034866B1 (https=)
IL (1) IL244321B (https=)
MX (1) MX370588B (https=)
NZ (2) NZ748260A (https=)
TW (1) TWI692477B (https=)
WO (1) WO2015030847A1 (https=)
ZA (1) ZA201601697B (https=)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR093580A1 (es) * 2013-08-30 2015-06-10 Ptc Therapeutics Inc Inhibidores bmi-1 de pirimidina sustituidos
GB201321736D0 (en) * 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
EP3365334B1 (en) 2015-10-21 2024-07-17 Otsuka Pharmaceutical Co., Ltd. Benzolactam compounds as protein kinase inhibitors
US10851082B2 (en) 2015-10-28 2020-12-01 Northwestern University Substituted aromatic n-heterocyclic compounds as inhibitors of mitogen-activated protein kinase interacting kinase 1 (MNK1) and 2 (MNK2)
EP3405464B1 (en) 2016-01-22 2019-12-04 Janssen Pharmaceutica NV New 6-membered heteroaromatic substituted cyanoindoline derivatives as nik inhibitors
ES2775449T3 (es) 2016-01-22 2020-07-27 Janssen Pharmaceutica Nv Nuevos derivados de cianoindolina sustituida como inhibidores de nik
AU2017269335B2 (en) 2016-05-26 2021-07-01 Recurium Ip Holdings, Llc EGFR inhibitor compounds
ES2837157T3 (es) 2016-06-30 2021-06-29 Janssen Pharmaceutica Nv Derivados de cianoindolina como inhibidores de NIK
WO2018002217A1 (en) 2016-06-30 2018-01-04 Janssen Pharmaceutica Nv Heteroaromatic derivatives as nik inhibitors
GB201706327D0 (en) 2017-04-20 2017-06-07 Otsuka Pharma Co Ltd A pharmaceutical compound
US10793551B2 (en) 2017-10-19 2020-10-06 Effector Therapeutics Inc. Benzimidazole-indole inhibitors of Mnk1 and Mnk2
MD3784664T2 (ro) 2018-04-26 2025-06-30 Pfizer Derivați de 2-amino-piridină sau de 2-amino-pirimidină utilizați ca inhibitori de kinaze dependente de cicline
EP3564235A1 (en) * 2018-05-03 2019-11-06 Northwestern University Substituted aromatic n-heterocyclic compounds as inhibitors of mitogen-activated protein kinase interacting kinase 1 (mnk1) and 2 (mnk2)
EP3813784B1 (en) * 2018-06-07 2024-01-10 The Regents Of The University Of Michigan Prc1 inhibitors and prc1 inhibitors for use in methods of treatment therewith
CN113164479A (zh) 2018-08-17 2021-07-23 Ptc医疗公司 用于治疗胰腺癌的方法
US11066404B2 (en) 2018-10-11 2021-07-20 Incyte Corporation Dihydropyrido[2,3-d]pyrimidinone compounds as CDK2 inhibitors
WO2020168197A1 (en) 2019-02-15 2020-08-20 Incyte Corporation Pyrrolo[2,3-d]pyrimidinone compounds as cdk2 inhibitors
EA202192117A1 (ru) * 2019-02-28 2021-11-23 ПиТиСи ТЕРАПЬЮТИКС, ИНК. Способ лечения множественной миеломы
WO2020180959A1 (en) 2019-03-05 2020-09-10 Incyte Corporation Pyrazolyl pyrimidinylamine compounds as cdk2 inhibitors
WO2020205560A1 (en) 2019-03-29 2020-10-08 Incyte Corporation Sulfonylamide compounds as cdk2 inhibitors
US11440914B2 (en) 2019-05-01 2022-09-13 Incyte Corporation Tricyclic amine compounds as CDK2 inhibitors
WO2020223558A1 (en) 2019-05-01 2020-11-05 Incyte Corporation Tricyclic amine compounds as cdk2 inhibitors
MX2021013531A (es) 2019-05-05 2022-02-11 Qilu Regor Therapeutics Inc Inhibidores de cdk.
CN114269742B (zh) * 2019-07-10 2024-07-16 常州千红生化制药股份有限公司 作为治疗剂的4-(咪唑并[1,2-a]吡啶-3-基)-N-(吡啶基)嘧啶-2-胺的衍生物
EP4003992A1 (en) * 2019-07-24 2022-06-01 Merck Patent GmbH 4-(imidazo[1,2-a]pyridin-3-yl) -pyrimidine derivatives
TW202115024A (zh) 2019-08-14 2021-04-16 美商英塞特公司 作為cdk2 抑制劑之咪唑基嘧啶基胺化合物
AU2020364007A1 (en) 2019-10-11 2022-04-28 Incyte Corporation Bicyclic amines as CDK2 inhibitors
US11981671B2 (en) 2021-06-21 2024-05-14 Incyte Corporation Bicyclic pyrazolyl amines as CDK2 inhibitors
US11976073B2 (en) 2021-12-10 2024-05-07 Incyte Corporation Bicyclic amines as CDK2 inhibitors
WO2023107705A1 (en) 2021-12-10 2023-06-15 Incyte Corporation Bicyclic amines as cdk12 inhibitors
WO2023250439A1 (en) * 2022-06-22 2023-12-28 Tempest Therapeutics, Inc. Trex1 inhibitors and uses thereof
WO2025024388A1 (en) 2023-07-21 2025-01-30 Accutar Biotechnology Inc. Aminopyrimidine derivatives as cyclin-dependent kinase inhibitors

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110039873A1 (en) 2009-06-08 2011-02-17 Gaeta Federico C A SUBSTITUTED PYRAZOLO[1,5-a] PYRIDINE COMPOUNDS HAVING MULTI-TARGET ACTIVITY

Family Cites Families (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH593266A5 (https=) 1973-09-20 1977-11-30 Delalande Sa
US6162432A (en) 1991-10-07 2000-12-19 Biogen, Inc. Method of prophylaxis or treatment of antigen presenting cell driven skin conditions using inhibitors of the CD2/LFA-3 interaction
HK1006056A1 (en) 1991-10-07 1999-02-05 Astellas Us Llc Method of prophylaxis or treatment of antigen presenting cell driven skin conditions using inhibitors of the CD2/LFA-3 interaction
JP2896532B2 (ja) * 1994-08-13 1999-05-31 ユーハン コーポレーション 新規なピリミジン誘導体およびその製造方法
IN188411B (https=) 1997-03-27 2002-09-21 Yuhan Corp
KR100272471B1 (ko) * 1998-11-17 2000-11-15 김선진 신규의 피리미딘 유도체 및 그의 제조방법
AU5636900A (en) * 1999-06-30 2001-01-31 Merck & Co., Inc. Src kinase inhibitor compounds
GB9919778D0 (en) * 1999-08-21 1999-10-27 Zeneca Ltd Chemical compounds
WO2001025220A1 (en) 1999-10-07 2001-04-12 Amgen Inc. Triazine kinase inhibitors
ATE311385T1 (de) * 1999-10-27 2005-12-15 Novartis Pharma Gmbh Thiazol und imidazo(4,5-b)pyridin verbindungen und ihre verwendung als pharmazeutika
EP1257546A1 (en) 2000-02-17 2002-11-20 Amgen Inc. Kinase inhibitors
EP1274705A1 (en) * 2000-03-29 2003-01-15 Cyclacel Limited 2-substituted 4-heteroaryl-pyrimidines and their use in the treatment of proliferative disorders
EP1317450B1 (en) 2000-09-15 2006-11-22 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
CA2423050A1 (en) 2000-09-20 2002-03-28 Ortho-Mcneil Pharmaceutical, Inc. Pyrazine derivatives as modulators of tyrosine kinases
US6716851B2 (en) 2000-12-12 2004-04-06 Cytovia, Inc. Substituted 2-aryl-4-arylaminopyrimidines and analogs as activators or caspases and inducers of apoptosis and the use thereof
GB0103926D0 (en) 2001-02-17 2001-04-04 Astrazeneca Ab Chemical compounds
EP1423388B1 (en) * 2001-02-20 2008-12-03 AstraZeneca AB 2-arylamino-pyrimidines for the treatment of gsk3-related disorders
DE60239097D1 (de) 2001-03-02 2011-03-17 Gpc Biotech Ag Drei-hybrid-assaysystem
CA2450555A1 (en) 2001-06-25 2003-01-03 Merck & Co., Inc. (pyrimidyl)(phenyl)substituted fused heteroaryl p38 inhibiting and pkg kinase inhibiting compounds
WO2003004492A1 (en) 2001-07-03 2003-01-16 Vertex Pharmaceuticals Incorporated Isoxazolyl-pyrimidines as inhibitors of src and lck protein kinases
WO2003011837A1 (en) * 2001-08-01 2003-02-13 Merck & Co., Inc. Tyrosine kinase inhibitors
WO2004002963A1 (ja) 2002-06-28 2004-01-08 Nippon Shinyaku Co., Ltd. アミド誘導体及び医薬
GB0215844D0 (en) * 2002-07-09 2002-08-14 Novartis Ag Organic compounds
WO2004007407A2 (en) 2002-07-11 2004-01-22 Fluorous Technologies Incorporated Fluorous tagging and scavenging reactants and methods of synthesis and use thereof
US20040110821A1 (en) 2002-08-07 2004-06-10 Konkel Michael J. GAL3 receptor antagonists for the treatment of affective disorders
UA80296C2 (en) 2002-09-06 2007-09-10 Biogen Inc Imidazolopyridines and methods of making and using the same
EP1551842A1 (en) 2002-10-15 2005-07-13 Smithkline Beecham Corporation Pyradazine compounds as gsk-3 inhibitors
US7169781B2 (en) 2003-10-17 2007-01-30 Hoffmann-La Roche Inc. Imidazole derivatives and their use as pharmaceutical agents
NZ546058A (en) 2004-01-12 2010-09-30 Ym Biosciences Australia Pty Benzimidazole and other fused ring derivatives as selective janus kinase inhibitors
JP2007520558A (ja) * 2004-02-04 2007-07-26 スミスクライン・ビーチャム・コーポレイション キナーゼ阻害剤として有用なピリミジノン化合物
TWI372624B (en) 2004-03-30 2012-09-21 Vertex Pharma Azaindoles useful as inhibitors of jak and other protein kinases
JP2006045119A (ja) 2004-08-04 2006-02-16 Toray Ind Inc ピラジン誘導体及びそれを有効成分とする腎炎治療薬
US7855205B2 (en) 2004-10-29 2010-12-21 Janssen Pharmaceutica Nv Pyrimidinyl substituted fused-pyrrolyl compounds useful in treating kinase disorders
WO2006093247A1 (ja) 2005-02-28 2006-09-08 Japan Tobacco Inc. Ｓｙｋ阻害活性を有する新規なアミノピリジン化合物
KR20080004488A (ko) 2005-03-10 2008-01-09 바이엘 파마슈티칼스 코포레이션 과다증식성 장애 치료용 피리미딘 유도체
CA2654358A1 (en) 2006-06-22 2007-12-27 Biovitrum Ab (Publ) Pyridine and pyrazine derivatives as mnk kinase inhibitors
CN101516873A (zh) 2006-10-03 2009-08-26 神经研究公司 用作钾通道调节剂的吲唑基衍生物
CA2665398A1 (en) 2006-10-03 2008-04-10 Neurosearch A/S Indazolyl derivatives useful as potassium channel modulating agents
US7968556B2 (en) 2006-10-19 2011-06-28 Signal Pharmaceuticals, Llc Heteroaryl compounds, compositions thereof, and methods of treatment therewith
CA2672518A1 (en) 2006-12-22 2008-07-03 Novartis Ag Organic compounds and their uses
AR065015A1 (es) 2007-01-26 2009-05-13 Smithkline Beecham Corp Derivados de antranilamida, composiciones farmaceuticas que los contienen, y usos para el tratamiento del cancer
CA2676715A1 (en) 2007-02-12 2008-08-21 Merck & Co., Inc. Piperazine derivatives for treatment of ad and related conditions
WO2008132502A1 (en) 2007-04-25 2008-11-06 Astrazeneca Ab Pyrazolyl-amino-substituted pyrimidines and their use for the treatment of cancer
GB0714573D0 (en) 2007-07-26 2007-09-05 Imp Innovations Ltd Marker gene
WO2009037247A1 (en) 2007-09-17 2009-03-26 Neurosearch A/S Pyrazine derivatives and their use as potassium channel modulators
WO2009064835A1 (en) 2007-11-16 2009-05-22 Incyte Corporation 4-pyrazolyl-n-arylpyrimidin-2-amines and 4-pyrazolyl-n-heteroarylpyrimidin-2-amines as janus kinase inhibitors
CA2707989A1 (en) 2007-12-07 2009-06-11 Novartis Ag Pyrazole derivatives and use thereof as inhibitors of cyclin dependent kinases
DE102008005493A1 (de) * 2008-01-22 2009-07-23 Merck Patent Gmbh 4-(Pyrrolo[2,3-c] pyridine-3-yl)-pyrimidin-2-yl-amin-derivate
GB0801416D0 (en) 2008-01-25 2008-03-05 Piramed Ltd Pharmaceutical compounds
NZ588830A (en) 2008-04-22 2012-11-30 Portola Pharm Inc Inhibitors of protein kinases
ES2605815T3 (es) 2008-07-01 2017-03-16 Ptc Therapeutics, Inc. Moduladores de la expresión de la proteína Bmi-1
CN102177154A (zh) 2008-09-02 2011-09-07 神经研究公司 吡唑基-嘧啶衍生物及其作为钾通道调节剂的应用
WO2010061903A1 (ja) 2008-11-27 2010-06-03 塩野義製薬株式会社 Pi3k阻害活性を有するピリミジン誘導体およびピリジン誘導体
US20120165309A1 (en) 2009-02-12 2012-06-28 Astellas Pharma Inc. Hetero ring derivative
SG174527A1 (en) 2009-03-27 2011-11-28 Pathway Therapeutics Inc Pyrimidinyl and 1,3,5-triazinyl benzimidazole sulfonamides and their use in cancer therapy
US8536180B2 (en) 2009-05-27 2013-09-17 Abbvie Inc. Pyrimidine inhibitors of kinase activity
RS57869B1 (sr) 2009-06-17 2018-12-31 Vertex Pharma Inhibitori replikacije virusa gripa
US8486939B2 (en) 2009-07-07 2013-07-16 Pathway Therapeutics Inc. Pyrimidinyl and 1,3,5-triazinyl benzimidazoles and their use in cancer therapy
CA2767089A1 (en) * 2009-07-15 2011-01-20 Abbott Laboratories Pyrrolopyridine inhibitors of kinases
JP5415176B2 (ja) 2009-08-06 2014-02-12 株式会社マキタ スイッチ
MX2012008083A (es) 2010-01-12 2012-08-15 Ab Science Inhibidores de triazol y oxazol quinaza.
UY33213A (es) 2010-02-18 2011-09-30 Almirall Sa Derivados de pirazol como inhibidores de jak
ES2365960B1 (es) 2010-03-31 2012-06-04 Palobiofarma, S.L Nuevos antagonistas de los receptores de adenosina.
KR101759762B1 (ko) 2010-08-10 2017-07-19 아스텔라스세이야쿠 가부시키가이샤 헤테로환 화합물
CN103221408A (zh) 2010-09-13 2013-07-24 诺瓦提斯公司 三嗪-*二唑类化合物
WO2012050884A2 (en) 2010-09-28 2012-04-19 President And Fellows Of Harvard College Cardiac glycosides are potent inhibitors of interferon-beta gene expression
CA2819373A1 (en) 2010-12-09 2012-06-14 Amgen Inc. Bicyclic compounds as pim inhibitors
PL2678332T3 (pl) 2011-02-25 2016-12-30 Pochodne diaminopirymidyny i sposoby ich wytwarzania
JP6116554B2 (ja) 2011-07-07 2017-04-19 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ がんの処置のための置換されたアザ複素環
US9695228B2 (en) 2012-11-21 2017-07-04 Janssen Biotech, Inc. EGFR and c-Met fibronectin type III domain binding molecules
UY35148A (es) 2012-11-21 2014-05-30 Amgen Inc Immunoglobulinas heterodiméricas
KR20220143164A (ko) 2012-11-21 2022-10-24 피티씨 테라퓨틱스, 인크. 치환된 리버스 피리미딘 ｂｍｉ-1 저해제
AR093580A1 (es) * 2013-08-30 2015-06-10 Ptc Therapeutics Inc Inhibidores bmi-1 de pirimidina sustituidos

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110039873A1 (en) 2009-06-08 2011-02-17 Gaeta Federico C A SUBSTITUTED PYRAZOLO[1,5-a] PYRIDINE COMPOUNDS HAVING MULTI-TARGET ACTIVITY

Also Published As

Publication number Publication date
AR093580A1 (es) 2015-06-10
EA034866B1 (ru) 2020-03-31
US20160214978A1 (en) 2016-07-28
NZ748260A (en) 2020-01-31
EP3039015A1 (en) 2016-07-06
EP3039015B1 (en) 2019-10-30
JP2016529292A (ja) 2016-09-23
AU2018271277A1 (en) 2018-12-20
AU2013399092A1 (en) 2016-03-17
IL244321A0 (en) 2016-04-21
MX2016002642A (es) 2016-08-12
BR112016004511A2 (pt) 2017-09-12
HK1226057A1 (zh) 2017-09-22
CA2922657A1 (en) 2015-03-05
CL2016000466A1 (es) 2016-10-21
KR20160048920A (ko) 2016-05-04
IL244321B (en) 2020-07-30
EP3039015A4 (en) 2017-01-11
AU2018271277B2 (en) 2020-07-16
WO2015030847A1 (en) 2015-03-05
JP2019059778A (ja) 2019-04-18
JP6728321B2 (ja) 2020-07-22
JP6524094B2 (ja) 2019-06-05
BR112016004511A8 (pt) 2021-11-30
CN105683166B (zh) 2020-06-16
EA201690502A1 (ru) 2016-08-31
NZ718055A (en) 2020-01-31
TW201512188A (zh) 2015-04-01
ZA201601697B (en) 2021-07-28
US10370371B2 (en) 2019-08-06
TWI692477B (zh) 2020-05-01
CA2922657C (en) 2022-04-12
CN105683166A (zh) 2016-06-15
MX370588B (es) 2019-12-16

Similar Documents

Publication Publication Date Title
KR102232595B1 (ko) 치환된 피리미딘 bmi-1 저해제
US11180483B2 (en) Substituted reverse pyrimidine Bmi-1 inhibitors
US10584115B2 (en) Substituted pyridine and pyrazine BMI-1 inhibitors
US9975878B2 (en) Substituted triazine BMI-1 inhibitors
BR112016004511B1 (pt) Composto, composto ou uma forma do mesmo, uso de um composto ou forma do mesmo, e composição farmacêutica para uso no tratamento de um câncer mediado por bmi-1

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E601 Decision to refuse application
PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601

X091 Application refused [patent]
AMND Amendment
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PX0901 Re-examination

St.27 status event code: A-2-3-E10-E12-rex-PX0901

PX0701 Decision of registration after re-examination

St.27 status event code: A-3-4-F10-F13-rex-PX0701

X701 Decision to grant (after re-examination)
GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20240323

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20240323